NCT03851640View on ClinicalTrials.gov

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

PHASE3RecruitingINTERVENTIONAL
Enrollment

417

Participants

Timeline

Start Date

April 12, 2019

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
MCRPC
Interventions
DRUG

HC-1119

oral

DRUG

placebo

oral

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Hinova Pharmaceuticals Inc.

INDUSTRY

NCT03851640 - A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). | Biotech Hunter | Biotech Hunter